Fractyl Health, Inc. announced preliminary results showing weight maintenance after GLP-1 drug discontinuation and the Revita procedure in the first patient of the REVEAL-1 cohort, with strong enrollment progress for the REMAIN-1 pivotal study expected to report mid-point analysis in Q2 2025.